|  |
March 2004 Stock Report
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| GENOME THERAPEUTICS CORP |
$5.62 |
78% |
304% |
$415 |
$29 |
$2 |
$388 |
$6.2 |
-$5 |
5.5 |
Feb-82 |
0.5 |
$11.00 |
$90 |
| HUMAN GENOME SCIENCES |
$12.53 |
70% |
46% |
$1,622 |
$981 |
$504 |
$1,145 |
$1.0 |
-$196 |
5.0 |
Dec-93 |
4.2 |
$3.00 |
$176 |
| INCYTE CORP. |
$8.31 |
81% |
184% |
$604 |
$305 |
$167 |
$466 |
$1.0 |
-$163 |
1.9 |
Nov-93 |
4.4 |
$1.88 |
$47 |
| MILLENNIUM PHARMACEUTICALS |
$16.90 |
85% |
105% |
$5,137 |
$945 |
$207 |
$4,399 |
$2.9 |
-$586 |
1.6 |
May-96 |
5.6 |
$3.00 |
$273 |
| MYRIAD GENETICS |
$16.17 |
87% |
60% |
$439 |
$72 |
$0 |
$367 |
$0.7 |
-$40 |
1.8 |
Oct-95 |
1.8 |
$9.00 |
$163 |
| 1st Generation Genomics Average |
|
80% |
140% |
$1,643 |
$466 |
|
$1,353 |
$2.4 |
-$198 |
3.2 |
|
3.3 |
|
|
| 1st Generation Genomics Median |
|
83% |
102% |
$521 |
$188 |
|
$427 |
$1.0 |
-$101 |
1.8 |
|
3.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACLARA BIOSCIENCES |
$4.00 |
86% |
96% |
$144 |
$88 |
$1 |
$56 |
$0.9 |
-$15 |
6.0 |
Mar-00 |
0.2 |
$21.00 |
$682 |
| AFFYMETRIX |
$33.77 |
93% |
25% |
$2,036 |
$467 |
$388 |
$1,957 |
$2.2 |
na |
na |
Jun-96 |
4.5 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$6.90 |
70% |
110% |
$197 |
$70 |
$0 |
$128 |
$0.3 |
-$80 |
0.9 |
Dec-99 |
0.4 |
$16.00 |
$333 |
| CEPHEID |
$9.31 |
69% |
135% |
$388 |
$81 |
$2 |
$309 |
$1.7 |
-$18 |
4.5 |
Jun-00 |
1.6 |
$6.00 |
$158 |
| CIPHERGEN BIOSYSTEMS |
$8.40 |
60% |
68% |
$244 |
$50 |
$32 |
$226 |
$0.7 |
-$27 |
1.9 |
Sep-00 |
0.5 |
$16.00 |
$417 |
| COMBIMATRIX CORP. |
$5.98 |
64% |
229% |
$165 |
$17 |
$0 |
$148 |
$2.5 |
-$16 |
1.1 |
na |
na |
na |
na |
| COMPUGEN LTD |
$6.50 |
80% |
240% |
$171 |
$20 |
$0 |
$151 |
$0.9 |
-$14 |
1.4 |
Sep-00 |
0.7 |
$10.00 |
$0 |
| ILLUMINA |
$7.50 |
73% |
214% |
$247 |
$34 |
$26 |
$238 |
$6.6 |
-$16 |
2.1 |
Jul-00 |
0.5 |
$16.00 |
$515 |
| NANOGEN |
$7.53 |
50% |
549% |
$235 |
$31 |
$1 |
$205 |
$1.5 |
-$24 |
1.3 |
Apr-98 |
0.7 |
$11.00 |
$197 |
| ORCHID BIOSCIENCES |
$10.00 |
70% |
400% |
$218 |
$18 |
$2 |
$202 |
$0.5 |
-$8 |
2.3 |
May-00 |
1.3 |
$8.00 |
$263 |
| SEQUENOM |
$2.87 |
64% |
58% |
$115 |
$64 |
$12 |
$62 |
$0.3 |
-$40 |
1.6 |
Feb-00 |
0.1 |
$26.00 |
$609 |
| TRANSGENOMIC |
$1.96 |
59% |
3% |
$50 |
$3 |
$0 |
$47 |
$0.2 |
-$34 |
0.1 |
Jul-00 |
0.1 |
$15.00 |
$317 |
| Genomic Supply Average |
|
70% |
177% |
$351 |
$79 |
|
$311 |
$1.5 |
-$27 |
2.1 |
|
1.0 |
|
|
| Genomic Supply Median |
|
70% |
110% |
$197 |
$34 |
|
$151 |
$0.9 |
-$17 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ARENA PHARMACEUTICALS |
$6.50 |
76% |
-6% |
$166 |
$159 |
$0 |
$7 |
$0.0 |
-$58 |
2.7 |
Jul-00 |
0.4 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$14.51 |
81% |
63% |
$1,056 |
$782 |
$0 |
$274 |
$0.4 |
-$54 |
14.4 |
Feb-00 |
0.1 |
$225.00 |
na |
| CURAGEN CORP. |
$6.24 |
65% |
81% |
$312 |
$345 |
$150 |
$117 |
$0.4 |
-$70 |
4.9 |
Mar-98 |
1.1 |
$5.75 |
$143 |
| DECODE GENETICS |
$10.63 |
77% |
445% |
$579 |
$75 |
$63 |
$568 |
$1.4 |
-$42 |
1.8 |
Jul-00 |
0.6 |
$18.00 |
$818 |
| EXELIXIS |
$8.52 |
87% |
36% |
$607 |
$240 |
$111 |
$478 |
$0.8 |
-$93 |
2.6 |
Apr-00 |
0.7 |
$13.00 |
$520 |
| GENAISSANCE PHARMACEUTICALS |
$3.49 |
79% |
166% |
$80 |
$19 |
$9 |
$71 |
$0.7 |
-$16 |
1.1 |
Aug-00 |
0.3 |
$13.00 |
$288 |
| GENE LOGIC |
$5.05 |
59% |
-5% |
$157 |
$115 |
$1 |
$43 |
$0.1 |
-$20 |
5.9 |
Nov-97 |
0.6 |
$8.00 |
$109 |
| GENENCOR INTERNATIONAL |
$13.31 |
76% |
25% |
$789 |
$203 |
$99 |
$686 |
$0.6 |
na |
na |
Jul-00 |
0.7 |
$18.00 |
$1,045 |
| LARGE SCALE BIOLOGY CORP. |
$1.68 |
58% |
344% |
$43 |
$8 |
$0 |
$35 |
$0.5 |
-$28 |
0.3 |
Aug-00 |
0.1 |
$17.00 |
$388 |
| LEXICON GENETICS |
$6.27 |
77% |
53% |
$397 |
$918 |
$56 |
($465) |
($0.7) |
-$47 |
19.4 |
Apr-00 |
0.3 |
$22.00 |
$1,037 |
| LYNX THERAPEUTICS |
$4.53 |
54% |
129% |
$24 |
$6 |
$0 |
$18 |
$0.2 |
-$15 |
0.4 |
na |
na |
na |
na |
| MAXYGEN |
$9.48 |
61% |
29% |
$332 |
$121 |
$0 |
$210 |
$0.8 |
-$38 |
3.2 |
Dec-99 |
0.6 |
$16.00 |
$465 |
| NUVELO |
$12.54 |
76% |
423% |
$326 |
$114 |
$20 |
$232 |
$3.7 |
-$38 |
3.0 |
Sep-97 |
0.9 |
$14.00 |
$175 |
| PARADIGM GENETICS |
$1.26 |
65% |
241% |
$41 |
$17 |
$8 |
$32 |
$0.2 |
-$9 |
2.0 |
May-00 |
0.2 |
$7.00 |
$177 |
| RIGEL PHARMACEUTICALS |
$22.13 |
84% |
224% |
$396 |
$112 |
$4 |
$288 |
$2.3 |
-$48 |
2.3 |
Nov-00 |
3.2 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$6.18 |
74% |
100% |
$154 |
$44 |
$0 |
$110 |
$1.9 |
-$7 |
6.5 |
Apr-00 |
0.4 |
$15.00 |
$312 |
| ZYMOGENETICS |
$15.46 |
81% |
63% |
$815 |
$303 |
$0 |
$513 |
$1.4 |
-$73 |
4.1 |
Feb-01 |
1.3 |
$12.00 |
$547 |
| Genomic Targets Average |
|
72% |
142% |
$369 |
$211 |
|
$189 |
$0.9 |
-$41 |
4.7 |
|
0.7 |
|
|
| Genomic Targets Median |
|
76% |
91% |
$319 |
$115 |
|
$113 |
$0.6 |
-$38 |
2.7 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXION PHARMACEUTICALS |
$23.77 |
91% |
80% |
$522 |
$227 |
$120 |
$414 |
$2.2 |
-$74 |
3.1 |
Feb-96 |
2.9 |
$8.25 |
$62 |
| ATHEROGENICS |
$22.87 |
99% |
154% |
$846 |
$133 |
$101 |
$813 |
$8.4 |
-$63 |
2.1 |
Aug-00 |
2.9 |
$8.00 |
$184 |
| AUTOIMMUNE |
$1.17 |
52% |
58% |
$20 |
$11 |
$0 |
$9 |
$4.5 |
-$0 |
27.0 |
Jan-93 |
0.1 |
$13.00 |
$129 |
| CONNETICS CORP. |
$22.02 |
86% |
46% |
$775 |
$120 |
$0 |
$655 |
$3.0 |
na |
na |
Feb-96 |
2.0 |
$11.00 |
$81 |
| CORTECH |
$3.07 |
94% |
17% |
$11 |
$12 |
$0 |
($1) |
($0.7) |
-$0 |
29.3 |
Nov-92 |
0.1 |
$40.00 |
$116 |
| CYPRESS BIOSCIENCE |
$11.50 |
68% |
358% |
$258 |
$24 |
$0 |
$234 |
$15.6 |
-$29 |
0.8 |
Dec-83 |
0.1 |
$80.00 |
$33 |
| ICOS CORP. |
$36.93 |
77% |
101% |
$2,335 |
$419 |
$279 |
$2,195 |
$3.3 |
-$137 |
3.1 |
Jun-91 |
4.6 |
$8.00 |
$172 |
| INKINE PHARMACEUTICAL CO. |
$5.19 |
78% |
241% |
$252 |
$41 |
$0 |
$211 |
$3.7 |
na |
na |
na |
na |
na |
na |
| LA JOLLA PHARMACEUTICAL CO. |
$2.76 |
53% |
130% |
$169 |
$61 |
$2 |
$110 |
$0.9 |
-$34 |
1.8 |
Jun-94 |
0.6 |
$5.00 |
$43 |
| PROTEIN DESIGN LABS |
$23.82 |
93% |
221% |
$2,238 |
$504 |
$260 |
$1,994 |
$3.6 |
-$292 |
1.7 |
Jan-92 |
3.2 |
$7.50 |
$191 |
| TANOX |
$14.89 |
65% |
35% |
$654 |
$164 |
$15 |
$505 |
$4.3 |
-$11 |
14.6 |
Apr-00 |
0.5 |
$28.50 |
$1,193 |
| Autoimmune Average |
|
78% |
131% |
$734 |
$156 |
|
$649 |
$4.4 |
-$71 |
9.3 |
|
1.7 |
|
|
| Autoimmune Median |
|
82% |
100% |
$390 |
$90 |
|
$324 |
$3.4 |
-$31 |
2.6 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALLOS THERAPEUTICS |
$4.80 |
81% |
17% |
$149 |
$41 |
$0 |
$108 |
$1.8 |
na |
na |
Mar-00 |
0.3 |
$18.00 |
$604 |
| ANTIGENICS |
$10.66 |
67% |
30% |
$480 |
$149 |
$16 |
$348 |
$1.6 |
-$72 |
2.1 |
Feb-00 |
0.6 |
$18.00 |
$429 |
| APHTON CORP. |
$4.70 |
47% |
106% |
$177 |
$72 |
$11 |
$115 |
$2.3 |
-$22 |
3.2 |
na |
na |
na |
na |
| ARIAD PHARMACEUTICALS |
$9.55 |
84% |
602% |
$450 |
$104 |
$8 |
$354 |
$6.8 |
-$23 |
4.6 |
May-94 |
1.2 |
$8.00 |
$124 |
| AVI BIOPHARMA |
$3.03 |
41% |
5% |
$109 |
$38 |
$0 |
$71 |
$0.7 |
-$12 |
3.1 |
Jun-97 |
0.3 |
$9.00 |
$103 |
| BIOMIRA |
$1.87 |
38% |
58% |
$117 |
$20 |
$0 |
$97 |
$0.6 |
-$14 |
1.4 |
Jun-87 |
0.4 |
$4.40 |
$43 |
| BOSTON LIFE SCIENCES |
$1.22 |
41% |
28% |
$40 |
$11 |
$4 |
$32 |
$2.7 |
-$8 |
1.4 |
na |
na |
na |
na |
| CANCERVAX |
$10.61 |
79% |
na |
$283 |
$109 |
$8 |
$182 |
$1.2 |
-$44 |
2.5 |
Oct-03 |
0.9 |
$12.00 |
$308 |
| CELGENE CORP. |
$47.65 |
97% |
80% |
$3,882 |
$685 |
$400 |
$3,598 |
$5.3 |
na |
na |
Jul-87 |
13.0 |
$3.66 |
$55 |
| CELL THERAPEUTICS |
$8.46 |
54% |
-3% |
$426 |
$97 |
$192 |
$520 |
$1.4 |
-$147 |
0.7 |
Mar-97 |
0.8 |
$10.00 |
$166 |
| CORIXA CORP. |
$6.40 |
65% |
1% |
$355 |
$154 |
$134 |
$335 |
$1.0 |
-$67 |
2.3 |
Oct-97 |
0.5 |
$13.00 |
$152 |
| CYTOGEN CORP. |
$12.37 |
81% |
331% |
$160 |
$32 |
$0 |
$129 |
$2.1 |
-$12 |
2.5 |
Jun-86 |
1.0 |
$13.00 |
$148 |
| DENDREON CORP. |
$13.30 |
84% |
170% |
$768 |
$252 |
$2 |
$518 |
$3.5 |
na |
na |
Jun-00 |
1.3 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$10.70 |
72% |
565% |
$143 |
$35 |
$2 |
$109 |
$2.2 |
-$15 |
2.3 |
Jan-92 |
1.8 |
$6.00 |
$30 |
| ENTREMED |
$3.48 |
53% |
259% |
$129 |
$38 |
$0 |
$91 |
$2.1 |
-$24 |
1.6 |
Jun-96 |
0.2 |
$15.00 |
$182 |
| EXEGENICS |
$0.89 |
74% |
78% |
$14 |
$12 |
$0 |
$2 |
$0.2 |
-$6 |
2.0 |
na |
na |
na |
na |
| GENAERA CORP. |
$4.47 |
68% |
1342% |
$233 |
$14 |
$0 |
$220 |
$9.6 |
-$17 |
0.8 |
Dec-91 |
0.5 |
$9.00 |
$62 |
| GENITOPE |
$11.42 |
78% |
na |
$195 |
$0 |
$0 |
$195 |
$2.1 |
na |
na |
Oct-03 |
1.3 |
$9.00 |
$145 |
| GENTA INC. |
$10.50 |
59% |
48% |
$816 |
$86 |
$46 |
$776 |
$5.0 |
-$80 |
1.1 |
Dec-91 |
0.1 |
$100.00 |
$123 |
| GERON CORP. |
$9.40 |
56% |
142% |
$370 |
$111 |
$6 |
$265 |
$5.0 |
-$30 |
3.6 |
Jul-96 |
1.2 |
$8.00 |
$77 |
| ILEX ONCOLOGY |
$23.92 |
92% |
204% |
$934 |
$142 |
$38 |
$831 |
$3.8 |
-$71 |
2.0 |
Feb-97 |
2.0 |
$12.00 |
$143 |
| IMCLONE SYSTEMS |
$50.75 |
87% |
196% |
$3,777 |
$123 |
$240 |
$3,894 |
$9.2 |
-$105 |
1.2 |
Nov-91 |
7.3 |
$7.00 |
$107 |
| IMMUNOGEN |
$6.72 |
92% |
180% |
$273 |
$102 |
$0 |
$171 |
$1.5 |
-$5 |
19.5 |
Nov-89 |
0.7 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$4.05 |
42% |
43% |
$202 |
$18 |
$6 |
$190 |
$1.8 |
-$19 |
1.0 |
Oct-83 |
3.2 |
$1.25 |
$25 |
| MAXIM PHARMACEUTICALS |
$8.56 |
81% |
173% |
$240 |
$82 |
$2 |
$159 |
$1.7 |
-$40 |
2.1 |
Jul-96 |
1.1 |
$7.50 |
$50 |
| MEDAREX |
$8.97 |
90% |
185% |
$709 |
$370 |
$300 |
$639 |
$1.5 |
-$149 |
2.5 |
Jun-91 |
3.0 |
$3.00 |
$31 |
| NAPRO BIOTHERAPEUTICS |
$2.88 |
86% |
357% |
$89 |
$52 |
$6 |
$43 |
$0.8 |
-$44 |
1.2 |
Apr-94 |
0.6 |
$5.00 |
$41 |
| NEOPHARM |
$18.76 |
83% |
67% |
$435 |
$121 |
$0 |
$314 |
$3.0 |
-$52 |
2.3 |
Jan-96 |
5.9 |
$3.18 |
$28 |
| NEORX CORP. |
$4.38 |
61% |
484% |
$132 |
$28 |
$5 |
$108 |
$2.8 |
-$12 |
2.3 |
Aug-88 |
0.2 |
$28.00 |
$102 |
| OSI PHARMACEUTICALS |
$38.40 |
89% |
151% |
$1,497 |
$370 |
$310 |
$1,437 |
$3.0 |
-$160 |
2.3 |
Apr-86 |
6.4 |
$6.00 |
$53 |
| OXIGENE |
$9.30 |
48% |
528% |
$157 |
$19 |
$0 |
$138 |
$12.5 |
-$7 |
2.8 |
Oct-93 |
1.6 |
$6.00 |
$28 |
| PHARMION |
$22.54 |
91% |
na |
$539 |
$28 |
$13 |
$525 |
$8.9 |
-$52 |
0.5 |
Nov-03 |
1.6 |
$14.00 |
$358 |
| PRAECIS PHARMACEUTICALS |
$5.91 |
74% |
48% |
$308 |
$144 |
$33 |
$198 |
$1.1 |
-$64 |
2.2 |
Apr-00 |
0.6 |
$10.00 |
$400 |
| PROGENICS PHARMACEUTICALS |
$19.04 |
81% |
324% |
$319 |
$61 |
$0 |
$259 |
$2.2 |
-$39 |
1.6 |
Nov-97 |
2.4 |
$8.00 |
$70 |
| QLT |
$25.54 |
96% |
185% |
$1,773 |
$523 |
$173 |
$1,422 |
$4.3 |
na |
na |
Sep-86 |
23.6 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$5.40 |
55% |
3% |
$241 |
$65 |
$7 |
$182 |
$1.7 |
-$19 |
3.5 |
Mar-92 |
0.7 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$8.23 |
76% |
214% |
$331 |
$108 |
$0 |
$223 |
$2.1 |
-$22 |
5.0 |
Mar-01 |
1.2 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$8.35 |
81% |
309% |
$84 |
$27 |
$0 |
$57 |
$3.6 |
-$17 |
1.5 |
na |
na |
na |
na |
| SUPERGEN |
$12.80 |
92% |
378% |
$492 |
$27 |
$0 |
$465 |
$4.0 |
-$75 |
0.4 |
Mar-96 |
2.1 |
$6.00 |
$21 |
| VERNALIS |
$2.70 |
89% |
-2% |
$46 |
$67 |
$0 |
($21) |
($0.2) |
-$26 |
2.6 |
May-96 |
0.4 |
$7.20 |
$178 |
| XENOVA PLC |
$1.97 |
56% |
-20% |
$39 |
$27 |
$0 |
$12 |
$0.1 |
-$21 |
1.3 |
Jul-94 |
0.1 |
$16.00 |
$90 |
| Cancer Average |
|
72% |
207% |
$534 |
$111 |
|
$471 |
$3.1 |
-$44 |
2.6 |
|
2.4 |
|
|
| Cancer Median |
|
79% |
151% |
$257 |
$66 |
|
$192 |
$2.1 |
-$24 |
2.1 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CV THERAPEUTICS |
$15.13 |
36% |
-17% |
$476 |
$443 |
$298 |
$331 |
$1.3 |
-$140 |
3.2 |
Nov-96 |
1.9 |
$8.00 |
$48 |
| ENCYSIVE PHARMACEUTICALS |
$10.28 |
94% |
843% |
$541 |
$84 |
$0 |
$457 |
$5.0 |
-$35 |
2.4 |
Dec-93 |
1.5 |
$6.75 |
$88 |
| MEDICINES COMPANY |
$40.00 |
96% |
106% |
$2,223 |
$137 |
$0 |
$2,085 |
$11.0 |
na |
na |
Sep-00 |
2.5 |
$16.00 |
$506 |
| MYOGEN |
$10.95 |
57% |
na |
$290 |
$115 |
$4 |
$179 |
$3.1 |
-$61 |
1.9 |
Oct-03 |
0.8 |
$14.00 |
$358 |
| NITROMED |
$7.85 |
68% |
na |
$201 |
$35 |
$0 |
$166 |
$4.1 |
-$14 |
2.6 |
Nov-03 |
0.7 |
$11.00 |
$264 |
| QUESTCOR PHARMACEUTICALS |
$0.90 |
72% |
10% |
$40 |
$3 |
$4 |
$40 |
$0.8 |
-$15 |
0.2 |
na |
na |
na |
na |
| Cardiovascular Average |
|
71% |
235% |
$629 |
$136 |
|
$543 |
$4.2 |
-$53 |
2.1 |
|
1.5 |
|
|
| Cardiovascular Median |
|
72% |
100% |
$290 |
$84 |
|
$179 |
$3.1 |
-$25 |
2.2 |
|
1.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALBANY MOLECULAR RESEARCH |
$14.90 |
89% |
5% |
$472 |
$129 |
$58 |
$400 |
$0.5 |
na |
na |
Feb-99 |
1.5 |
$10.00 |
$280 |
| ARGONAUT TECHNOLOGIES |
$1.38 |
51% |
50% |
$28 |
$14 |
$0 |
$14 |
$0.1 |
-$3 |
4.9 |
Jul-00 |
0.1 |
$15.00 |
$253 |
| ARQULE |
$5.94 |
85% |
146% |
$171 |
$79 |
$7 |
$99 |
$0.4 |
-$20 |
3.9 |
Oct-96 |
0.5 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$9.00 |
94% |
116% |
$257 |
$36 |
$0 |
$221 |
$0.9 |
-$25 |
1.4 |
Nov-01 |
1.2 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$8.35 |
89% |
442% |
$179 |
$21 |
$0 |
$158 |
$3.4 |
-$13 |
1.6 |
Mar-94 |
1.3 |
$6.50 |
$47 |
| DISCOVERY PARTNERS INTERNATIONAL |
$6.15 |
91% |
137% |
$152 |
$74 |
$0 |
$78 |
$0.4 |
na |
na |
Jul-00 |
0.3 |
$18.00 |
$428 |
| KOSAN BIOSCIENCES |
$10.62 |
75% |
110% |
$307 |
$83 |
$3 |
$227 |
$1.7 |
-$2 |
41.3 |
Oct-00 |
0.8 |
$14.00 |
$341 |
| PHARMACOPEIA |
$20.12 |
93% |
143% |
$483 |
$140 |
$0 |
$343 |
$0.5 |
na |
na |
Dec-95 |
1.3 |
$16.00 |
$158 |
| SYMYX TECHNOLOGIES |
$28.70 |
96% |
100% |
$913 |
$139 |
$0 |
$774 |
$3.3 |
na |
na |
Nov-99 |
2.1 |
$14.00 |
$398 |
| VERTEX PHARMACEUTICALS |
$9.42 |
50% |
-14% |
$735 |
$586 |
$345 |
$494 |
$0.7 |
-$443 |
1.3 |
Jul-91 |
2.1 |
$4.50 |
$85 |
| Chemistry Average |
|
81% |
124% |
$370 |
$130 |
|
$281 |
$1.2 |
-$84 |
9.1 |
|
1.1 |
|
|
| Chemistry Median |
|
89% |
110% |
$257 |
$79 |
|
$221 |
$0.7 |
-$13 |
1.6 |
|
1.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADOLOR CORP. |
$15.06 |
67% |
27% |
$584 |
$213 |
$0 |
$371 |
$2.9 |
-$58 |
3.7 |
Nov-00 |
1.0 |
$15.00 |
$407 |
| CEPHALON |
$57.33 |
94% |
36% |
$3,207 |
$1,223 |
$1,419 |
$3,403 |
$2.1 |
na |
na |
Apr-91 |
3.2 |
$18.00 |
$155 |
| DOV PHARMACEUTICAL |
$15.52 |
83% |
154% |
$259 |
$49 |
$15 |
$225 |
$6.2 |
-$48 |
1.0 |
Apr-02 |
1.2 |
$13.00 |
$188 |
| GUILFORD PHARMACEUTICALS |
$7.28 |
76% |
116% |
$247 |
$82 |
$92 |
$257 |
$1.0 |
-$96 |
0.8 |
Jun-94 |
1.4 |
$5.33 |
$30 |
| INDEVUS PHARMACEUTICALS |
$6.05 |
78% |
163% |
$286 |
$76 |
$2 |
$212 |
$7.9 |
-$48 |
1.6 |
Mar-90 |
3.0 |
$2.00 |
$31 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$4.75 |
54% |
-24% |
$91 |
$3 |
$0 |
$89 |
$8.1 |
-$4 |
0.6 |
Feb-94 |
0.6 |
$8.00 |
$30 |
| NEUROCRINE BIOSCIENCES |
$59.09 |
95% |
34% |
$2,088 |
$458 |
$37 |
$1,666 |
$5.3 |
na |
na |
May-96 |
5.6 |
$10.50 |
$172 |
| NYMOX PHARMACEUTICAL |
$4.87 |
90% |
28% |
$117 |
$1 |
$0 |
$116 |
$5.5 |
-$3 |
0.3 |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$6.92 |
70% |
287% |
$245 |
$13 |
$0 |
$232 |
$7.7 |
-$27 |
0.5 |
Jul-00 |
0.6 |
$12.00 |
$319 |
| PHARMOS CORP. |
$4.04 |
80% |
411% |
$355 |
$62 |
$19 |
$311 |
$5.9 |
-$22 |
2.8 |
Jul-83 |
0.2 |
$20.00 |
$16 |
| STEMCELLS |
$1.68 |
54% |
77% |
$57 |
$4 |
$2 |
$55 |
$1.9 |
-$10 |
0.5 |
Mar-92 |
0.2 |
$11.00 |
$82 |
| TITAN PHARMACEUTICALS |
$5.02 |
85% |
187% |
$146 |
$48 |
$0 |
$98 |
$1.6 |
-$42 |
1.1 |
Jan-96 |
1.0 |
$5.00 |
$66 |
| CNS Average |
|
77% |
125% |
$640 |
$186 |
|
$586 |
$4.7 |
-$36 |
1.3 |
|
1.6 |
|
|
| CNS Median |
|
80% |
100% |
$247 |
$49 |
|
$225 |
$5.3 |
-$27 |
1.0 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ABGENIX |
$13.32 |
78% |
76% |
$1,176 |
$360 |
$200 |
$1,016 |
$2.5 |
-$212 |
1.7 |
Jul-98 |
6.7 |
$2.00 |
$86 |
| ACUSPHERE |
$8.35 |
51% |
na |
$119 |
$55 |
$1 |
$65 |
$1.1 |
-$27 |
2.1 |
Oct-03 |
0.6 |
$14.00 |
$200 |
| AEROGEN |
$3.62 |
57% |
202% |
$15 |
$1 |
$0 |
$14 |
$0.2 |
-$18 |
0.0 |
Nov-00 |
0.3 |
$12.00 |
$233 |
| ALKERMES |
$15.99 |
98% |
91% |
$1,427 |
$169 |
$123 |
$1,381 |
$3.2 |
-$84 |
2.0 |
Jul-91 |
3.2 |
$5.00 |
$70 |
| ANDRX CORP. |
$27.20 |
88% |
188% |
$1,974 |
$300 |
$13 |
$1,687 |
$0.8 |
na |
na |
Jun-96 |
9.1 |
$3.00 |
$155 |
| ARADIGM CORP. |
$2.35 |
67% |
99% |
$148 |
$31 |
$0 |
$117 |
$0.6 |
-$24 |
1.3 |
Jun-96 |
0.2 |
$11.00 |
$114 |
| ATRIX LABORATORIES |
$25.50 |
83% |
86% |
$528 |
$102 |
$0 |
$426 |
$2.7 |
na |
na |
na |
na |
na |
na |
| BIODELIVERY SCIENCES INTERNATIONAL |
$3.38 |
68% |
21% |
$24 |
$3 |
$1 |
$22 |
$1.2 |
-$4 |
0.6 |
na |
na |
na |
na |
| CIMA LABS |
$31.43 |
94% |
56% |
$457 |
$84 |
$0 |
$374 |
$1.4 |
-$39 |
2.1 |
Jul-94 |
3.5 |
$9.00 |
$66 |
| DEPOMED |
$7.83 |
92% |
226% |
$271 |
$45 |
$10 |
$236 |
$3.2 |
-$38 |
1.2 |
Nov-97 |
1.3 |
$6.10 |
$33 |
| DOR BIOPHARMA |
$0.84 |
53% |
-21% |
$29 |
$6 |
$0 |
$24 |
$5.9 |
-$4 |
1.3 |
na |
na |
na |
na |
| DURECT CORP. |
$3.39 |
76% |
123% |
$173 |
$62 |
$62 |
$173 |
$1.6 |
-$21 |
2.9 |
Sep-00 |
0.3 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$6.61 |
72% |
141% |
$121 |
$36 |
$39 |
$124 |
$1.0 |
-$37 |
1.0 |
Feb-89 |
1.3 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$15.43 |
84% |
27% |
$676 |
$115 |
$400 |
$961 |
$3.0 |
na |
na |
Feb-84 |
10.3 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$25.90 |
59% |
346% |
$500 |
$24 |
$2 |
$477 |
$3.2 |
na |
na |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY |
$1.38 |
47% |
5% |
$43 |
$11 |
$2 |
$34 |
$1.3 |
-$19 |
0.6 |
na |
na |
na |
na |
| GENETRONICS BIOMEDICAL |
$1.63 |
84% |
482% |
$96 |
$14 |
$0 |
$82 |
$4.1 |
-$7 |
1.9 |
na |
na |
na |
na |
| KOS PHARMACEUTICALS |
$40.74 |
69% |
136% |
$1,504 |
$270 |
$30 |
$1,264 |
$1.4 |
na |
na |
Mar-97 |
2.7 |
$15.00 |
$233 |
| MACROCHEM CORP. |
$1.35 |
71% |
165% |
$45 |
$7 |
$0 |
$37 |
$2.3 |
-$9 |
0.8 |
Feb-85 |
0.5 |
$3.00 |
$13 |
| MEDICIS PHARMACEUTICAL |
$32.21 |
97% |
-38% |
$1,531 |
$571 |
$471 |
$1,432 |
$4.6 |
na |
na |
na |
na |
na |
na |
| NASTECH PHARMACEUTICAL |
$13.18 |
90% |
67% |
$157 |
$26 |
$9 |
$140 |
$1.7 |
-$24 |
1.1 |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$21.52 |
89% |
263% |
$1,209 |
$292 |
$393 |
$1,310 |
$2.0 |
na |
na |
May-94 |
5.7 |
$3.75 |
$65 |
| NOVAVAX |
$5.86 |
68% |
41% |
$203 |
$30 |
$42 |
$216 |
$1.8 |
-$12 |
2.4 |
na |
na |
na |
na |
| NOVEN PHARMACEUTICALS |
$21.47 |
83% |
65% |
$498 |
$93 |
$0 |
$405 |
$1.3 |
na |
na |
May-88 |
39.0 |
$0.55 |
$5 |
| SEPRACOR |
$48.10 |
97% |
246% |
$4,099 |
$797 |
$1,471 |
$4,773 |
$4.9 |
-$136 |
5.9 |
Sep-91 |
9.6 |
$5.00 |
$168 |
| Delivery Average |
|
77% |
129% |
$681 |
$140 |
|
$672 |
$2.3 |
-$42 |
1.7 |
|
5.9 |
|
|
| Delivery Median |
|
80% |
99% |
$237 |
$50 |
|
$226 |
$1.8 |
-$22 |
1.3 |
|
2.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCED MAGNETICS |
$11.05 |
73% |
160% |
$86 |
$24 |
$0 |
$62 |
$2.8 |
-$4 |
6.7 |
na |
na |
na |
na |
| BIOSITE INC. |
$31.97 |
55% |
-9% |
$500 |
$62 |
$19 |
$457 |
$0.6 |
na |
na |
Feb-97 |
2.7 |
$12.00 |
$149 |
| CHOLESTECH CORP. |
$8.80 |
68% |
17% |
$123 |
$20 |
$0 |
$103 |
$0.5 |
-$16 |
1.3 |
Jun-92 |
1.8 |
$5.00 |
$32 |
| DIAGNOSTIC PRODUCTS CORP. |
$43.30 |
84% |
23% |
$1,256 |
$81 |
$19 |
$1,195 |
$0.5 |
na |
na |
Jun-82 |
10.8 |
$4.00 |
$43 |
| DIGENE CORP. |
$34.38 |
70% |
123% |
$669 |
$42 |
$4 |
$631 |
$2.1 |
na |
na |
May-96 |
3.0 |
$11.50 |
$128 |
| ENZO BIOCHEM |
$16.83 |
59% |
26% |
$506 |
$81 |
$0 |
$425 |
$1.9 |
-$6 |
13.5 |
Jun-80 |
19.3 |
$0.87 |
$8 |
| EPIX MEDICAL |
$20.75 |
89% |
159% |
$471 |
$81 |
$0 |
$390 |
$4.5 |
-$34 |
2.4 |
Feb-97 |
3.0 |
$7.00 |
$59 |
| EXACT SCIENCES CORP. |
$7.84 |
44% |
-19% |
$151 |
$76 |
$0 |
$75 |
$0.9 |
-$23 |
3.3 |
Jan-01 |
0.6 |
$14.00 |
$261 |
| GEN-PROBE INC. |
$33.35 |
84% |
178% |
$1,635 |
$176 |
$0 |
$1,459 |
$2.0 |
na |
na |
Sep-87 |
4.8 |
$7.00 |
$103 |
| HYCOR BIOMEDICAL |
$4.89 |
75% |
117% |
$40 |
$7 |
$0 |
$32 |
$0.2 |
na |
na |
na |
na |
na |
na |
| IDEXX LABORATORIES |
$56.87 |
95% |
59% |
$1,974 |
$242 |
$1 |
$1,733 |
$0.7 |
na |
na |
Jun-91 |
15.2 |
$3.75 |
$76 |
| IMMUCOR |
$18.12 |
75% |
-15% |
$357 |
$13 |
$16 |
$360 |
$1.0 |
na |
na |
na |
na |
na |
na |
| LUMINEX CORP. |
$9.05 |
67% |
86% |
$277 |
$40 |
$0 |
$236 |
$1.8 |
-$2 |
16.8 |
Mar-00 |
0.5 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$56.96 |
78% |
105% |
$1,664 |
$72 |
$40 |
$1,632 |
$4.3 |
na |
na |
Nov-93 |
8.1 |
$7.00 |
$54 |
| MATRITECH |
$1.44 |
48% |
-37% |
$52 |
$8 |
$3 |
$47 |
$0.7 |
-$9 |
0.9 |
Jul-92 |
0.3 |
$5.00 |
$22 |
| MERIDIAN BIOSCIENCE |
$10.19 |
79% |
30% |
$151 |
$5 |
$22 |
$168 |
$0.7 |
na |
na |
na |
na |
na |
na |
| ORASURE TECHNOLOGIES |
$10.39 |
87% |
54% |
$460 |
$65 |
$4 |
$399 |
$2.3 |
na |
na |
na |
na |
na |
na |
| QUIDEL CORP. |
$6.59 |
47% |
83% |
$207 |
$32 |
$10 |
$185 |
$0.7 |
na |
na |
Aug-81 |
0.7 |
$10.00 |
$19 |
| SONUS PHARMACEUTICALS |
$6.90 |
78% |
194% |
$125 |
$20 |
$0 |
$106 |
$2.6 |
-$10 |
1.9 |
Oct-95 |
1.0 |
$7.00 |
$60 |
| TRINITY BIOTECH PLC |
$3.80 |
57% |
65% |
$163 |
$2 |
$5 |
$166 |
$0.3 |
na |
na |
na |
na |
na |
na |
| Diagnostic/imag. Average |
|
70% |
70% |
$543 |
$57 |
|
$493 |
$1.6 |
-$13 |
5.8 |
|
5.1 |
|
|
| Diagnostic/imag. Median |
|
75% |
65% |
$277 |
$40 |
|
$236 |
$1.0 |
-$9 |
2.4 |
|
2.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AASTROM BIOSCIENCES |
$1.32 |
72% |
371% |
$95 |
$11 |
$0 |
$84 |
$1.9 |
-$10 |
1.2 |
Feb-97 |
0.2 |
$7.00 |
$88 |
| AVIGEN |
$5.47 |
69% |
72% |
$111 |
$88 |
$8 |
$31 |
$0.3 |
-$27 |
3.3 |
May-96 |
0.7 |
$8.00 |
$58 |
| CELL GENESYS |
$12.04 |
74% |
72% |
$479 |
$255 |
$148 |
$371 |
$1.4 |
-$68 |
3.7 |
Jan-93 |
1.1 |
$11.00 |
$120 |
| CORAUTUS GENETICS |
$6.70 |
87% |
338% |
$67 |
$10 |
$6 |
$63 |
$2.1 |
-$7 |
1.3 |
na |
na |
na |
na |
| GENVEC |
$3.47 |
77% |
131% |
$179 |
$28 |
$6 |
$156 |
$1.8 |
-$21 |
1.4 |
Dec-00 |
0.4 |
$9.50 |
$186 |
| INTROGEN THERAPEUTICS |
$8.58 |
76% |
319% |
$228 |
$37 |
$8 |
$199 |
$2.8 |
-$22 |
1.7 |
Oct-00 |
1.1 |
$8.00 |
$167 |
| SIRNA THERAPEUTICS |
$4.05 |
35% |
57% |
$129 |
$37 |
$4 |
$96 |
$1.4 |
-$24 |
1.5 |
Apr-96 |
0.4 |
$10.00 |
$59 |
| TARGETED GENETICS CORP. |
$2.17 |
49% |
417% |
$168 |
$22 |
$13 |
$159 |
$1.8 |
-$25 |
0.9 |
May-94 |
0.4 |
$6.00 |
$54 |
| TRANSGENE SA |
$4.00 |
85% |
196% |
$121 |
$50 |
$0 |
$71 |
$0.4 |
-$32 |
1.5 |
Mar-98 |
0.1 |
$43.50 |
$212 |
| TRANSKARYOTIC THERAPIES |
$17.20 |
91% |
207% |
$595 |
$186 |
$0 |
$409 |
$1.3 |
-$59 |
3.2 |
Oct-96 |
1.1 |
$15.00 |
$234 |
| VALENTIS |
$5.87 |
70% |
82% |
$34 |
$8 |
$0 |
$26 |
$1.4 |
-$12 |
0.6 |
Sep-97 |
0.5 |
$12.00 |
$161 |
| VICAL INC. |
$6.14 |
75% |
133% |
$123 |
$85 |
$11 |
$50 |
$0.3 |
-$28 |
3.1 |
Mar-93 |
1.2 |
$5.00 |
$52 |
| Gene therapy Average |
|
72% |
200% |
$194 |
$68 |
|
$143 |
$1.4 |
-$28 |
1.9 |
|
0.6 |
|
|
| Gene therapy Median |
|
75% |
133% |
$123 |
$37 |
|
$84 |
$1.4 |
-$24 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCIS |
$9.14 |
89% |
na |
$208 |
$67 |
$3 |
$144 |
$1.8 |
-$21 |
3.1 |
Oct-03 |
0.9 |
$10.00 |
$224 |
| AVANT IMMUNOTHERAPEUTICS |
$2.61 |
67% |
156% |
$193 |
$21 |
$0 |
$172 |
$2.9 |
-$11 |
1.9 |
May-86 |
0.7 |
$4.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$9.19 |
57% |
22% |
$369 |
$127 |
$198 |
$440 |
$1.5 |
-$126 |
1.0 |
Oct-96 |
1.5 |
$6.00 |
$55 |
| EPIMMUNE |
$2.42 |
56% |
188% |
$33 |
$6 |
$0 |
$26 |
$0.7 |
-$5 |
1.3 |
Nov-91 |
0.0 |
$91.00 |
$167 |
| GENELABS TECHNOLOGIES |
$2.69 |
83% |
112% |
$237 |
$28 |
$0 |
$209 |
$2.8 |
-$27 |
1.0 |
Jun-91 |
0.3 |
$9.13 |
$160 |
| IMMUNE RESPONSE CORP. |
$1.57 |
40% |
25% |
$65 |
$13 |
$8 |
$59 |
$1.3 |
-$30 |
0.4 |
May-90 |
0.1 |
$28.00 |
$77 |
| INTERMUNE |
$19.50 |
69% |
-3% |
$622 |
$218 |
$150 |
$553 |
$2.1 |
-$93 |
2.3 |
Mar-00 |
1.0 |
$20.00 |
$433 |
| INTRABIOTICS PHARMACEUTICALS - |
$16.80 |
87% |
678% |
$89 |
$27 |
$0 |
$62 |
$6.2 |
-$17 |
1.6 |
Apr-00 |
1.1 |
$15.00 |
$419 |
| MEDIMMUNE |
$23.08 |
55% |
-29% |
$5,729 |
$850 |
$681 |
$5,561 |
$3.4 |
na |
na |
May-91 |
15.0 |
$1.54 |
$114 |
| NABI BIOPHARMACEUTICALS |
$15.56 |
91% |
162% |
$890 |
$122 |
$27 |
$795 |
$1.1 |
-$26 |
4.6 |
na |
na |
na |
na |
| SIGA TECHNOLOGIES |
$1.96 |
66% |
69% |
$37 |
$2 |
$0 |
$35 |
$2.1 |
-$6 |
0.2 |
Sep-97 |
0.4 |
$5.00 |
$32 |
| TRIMERIS |
$14.75 |
27% |
-64% |
$318 |
$95 |
$0 |
$224 |
$2.2 |
-$60 |
1.6 |
Oct-97 |
1.2 |
$12.00 |
$120 |
| VAXGEN |
$11.34 |
77% |
209% |
$236 |
$22 |
$0 |
$215 |
$1.8 |
-$35 |
0.6 |
Jul-99 |
0.9 |
$13.00 |
$146 |
| VICURON PHARMACEUTICALS |
$22.75 |
93% |
122% |
$1,229 |
$172 |
$10 |
$1,066 |
$28.8 |
-$89 |
1.9 |
Sep-00 |
2.1 |
$11.00 |
$249 |
| VION PHARMACEUTICALS |
$3.96 |
94% |
1138% |
$217 |
$16 |
$0 |
$201 |
$6.9 |
-$13 |
1.2 |
Aug-95 |
1.0 |
$4.00 |
$32 |
| VIROLOGIC |
$3.03 |
69% |
153% |
$162 |
$11 |
$1 |
$151 |
$0.8 |
-$2 |
6.8 |
May-00 |
0.4 |
$7.00 |
$137 |
| VIROPHARMA INC. |
$2.30 |
48% |
59% |
$61 |
$124 |
$128 |
$65 |
$0.7 |
-$28 |
4.4 |
Nov-96 |
0.3 |
$7.00 |
$65 |
| XOMA LTD |
$5.14 |
48% |
37% |
$433 |
$87 |
$59 |
$405 |
$1.8 |
-$78 |
1.1 |
Jun-86 |
0.3 |
$16.00 |
$140 |
| Infection Average |
|
67% |
178% |
$618 |
$111 |
|
$577 |
$3.8 |
-$39 |
2.1 |
|
1.6 |
|
|
| Infection Median |
|
69% |
106% |
$217 |
$28 |
|
$201 |
$1.8 |
-$27 |
1.5 |
|
0.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMYLIN PHARMACEUTICALS |
$23.69 |
77% |
63% |
$2,223 |
$276 |
$177 |
$2,125 |
$9.4 |
-$69 |
4.0 |
Jan-92 |
1.7 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$7.52 |
55% |
-36% |
$483 |
$225 |
$125 |
$383 |
$1.4 |
-$103 |
2.2 |
Aug-99 |
0.6 |
$13.00 |
$449 |
| INSMED |
$3.13 |
73% |
480% |
$120 |
$30 |
$0 |
$90 |
$4.5 |
-$10 |
3.0 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$15.28 |
99% |
991% |
$327 |
$32 |
$0 |
$296 |
$12.3 |
-$9 |
3.4 |
Jul-00 |
1.5 |
$10.00 |
$194 |
| NPS PHARMACEUTICALS |
$28.52 |
78% |
71% |
$1,061 |
$306 |
$192 |
$947 |
$3.5 |
-$194 |
1.6 |
May-94 |
5.2 |
$5.50 |
$40 |
| SAVIENT PHARMACEUTICALS |
$3.83 |
57% |
52% |
$868 |
$30 |
$13 |
$851 |
$1.8 |
na |
na |
Sep-83 |
0.3 |
$13.00 |
$68 |
| VIVUS |
$6.15 |
83% |
51% |
$234 |
$36 |
$0 |
$198 |
$1.7 |
na |
na |
Apr-94 |
0.9 |
$7.00 |
$164 |
| ZONAGEN |
$2.82 |
65% |
156% |
$32 |
$23 |
$0 |
$9 |
$2.4 |
-$4 |
6.4 |
Mar-93 |
0.5 |
$5.50 |
$19 |
| Metabolic Average |
|
73% |
229% |
$669 |
$120 |
|
$612 |
$4.6 |
-$65 |
3.4 |
|
1.5 |
|
|
| Metabolic Median |
|
77% |
71% |
$327 |
$32 |
|
$296 |
$2.4 |
-$10 |
3.0 |
|
0.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMGEN |
$58.15 |
80% |
1% |
$74,436 |
$5,682 |
$3,080 |
$71,834 |
$5.6 |
na |
na |
Jun-83 |
166.1 |
$0.35 |
$175 |
| BIOGEN IDEC |
$55.60 |
93% |
69% |
$18,459 |
$1,027 |
$887 |
$18,320 |
$4.9 |
na |
na |
Sep-91 |
22.2 |
$2.50 |
$131 |
| CHIRON CORP. |
$44.01 |
77% |
14% |
$8,253 |
$675 |
$1,084 |
$8,662 |
$1.6 |
na |
na |
Aug-83 |
14.7 |
$3.00 |
$98 |
| GENENTECH |
$105.82 |
93% |
207% |
$55,528 |
$1,675 |
$412 |
$54,265 |
$8.7 |
na |
na |
Oct-80 |
73.0 |
$1.45 |
$246 |
| GENZYME CORP. |
$46.78 |
81% |
35% |
$10,571 |
$658 |
$1,436 |
$11,349 |
$2.0 |
na |
na |
Jun-86 |
18.7 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$55.45 |
79% |
39% |
$11,854 |
$933 |
$345 |
$11,267 |
$7.9 |
na |
na |
Jan-92 |
14.8 |
$3.75 |
$210 |
| Revenue-driven Average |
|
84% |
61% |
$29,850 |
$1,775 |
|
$29,283 |
$5.1 |
|
|
|
51.6 |
|
|
| Revenue-driven Median |
|
81% |
39% |
$11,854 |
$933 |
|
$11,349 |
$4.9 |
|
|
|
28.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| DIVERSA CORP. |
$8.92 |
73% |
-5% |
$384 |
$130 |
$20 |
$275 |
$0.8 |
-$18 |
7.2 |
Feb-00 |
0.4 |
$24.00 |
$840 |
| DYAX CORP. |
$10.29 |
71% |
502% |
$320 |
$45 |
$11 |
$286 |
$2.6 |
-$28 |
1.6 |
Aug-00 |
0.7 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$7.76 |
81% |
149% |
$434 |
$223 |
$230 |
$440 |
$1.0 |
-$102 |
2.2 |
May-91 |
0.8 |
$10.00 |
$104 |
| LIGAND PHARMACEUTICALS |
$20.10 |
96% |
244% |
$1,475 |
$103 |
$173 |
$1,544 |
$3.3 |
na |
na |
Nov-92 |
2.4 |
$8.27 |
$131 |
| NEUROGEN CORP. |
$8.53 |
72% |
136% |
$170 |
$48 |
$16 |
$138 |
$0.9 |
-$34 |
1.4 |
Oct-89 |
1.4 |
$6.00 |
$35 |
| ONYX PHARMACEUTICALS |
$40.49 |
96% |
397% |
$1,395 |
$265 |
$0 |
$1,130 |
$70.7 |
-$47 |
5.6 |
May-96 |
3.4 |
$12.00 |
$105 |
| REGENERON PHARMACEUTICALS |
$13.58 |
61% |
-30% |
$755 |
$295 |
$214 |
$673 |
$10.5 |
-$78 |
3.8 |
Apr-91 |
0.6 |
$22.00 |
$330 |
| TULARIK |
$24.55 |
99% |
443% |
$1,645 |
$196 |
$28 |
$1,478 |
$3.6 |
-$102 |
1.9 |
Dec-99 |
1.8 |
$14.00 |
$636 |
| Screening Average |
|
81% |
229% |
$822 |
$163 |
|
$745 |
$11.7 |
-$58 |
3.4 |
|
1.4 |
|
|
| Screening Median |
|
81% |
149% |
$434 |
$130 |
|
$440 |
$2.6 |
-$41 |
2.1 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
3/31/04 Close |
% of 52wk High |
% change from 3/24/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CARRINGTON LABORATORIES |
$4.25 |
66% |
321% |
$44 |
$2 |
$5 |
$47 |
$0.2 |
-$4 |
0.5 |
na |
na |
na |
na |
| CELLEGY PHARMACEUTICALS |
$3.97 |
57% |
-4% |
$79 |
$13 |
$0 |
$67 |
$3.3 |
-$16 |
0.8 |
Aug-95 |
0.6 |
$6.25 |
$24 |
| CURATIVE HEALTH SERVICES |
$13.40 |
69% |
-21% |
$172 |
$8 |
$0 |
$164 |
$0.4 |
na |
na |
Jun-91 |
1.8 |
$7.50 |
$74 |
| LIFECELL CORP. |
$8.20 |
88% |
242% |
$210 |
$14 |
$0 |
$196 |
$1.1 |
na |
na |
Feb-92 |
1.1 |
$7.75 |
$27 |
| LIFECORE BIOMEDICAL |
$7.39 |
90% |
14% |
$95 |
$6 |
$0 |
$90 |
$0.4 |
na |
na |
na |
na |
na |
na |
| Wound Average |
|
74% |
110% |
$120 |
$9 |
|
$113 |
$1.1 |
-$10 |
0.7 |
|
1.2 |
|
|
| Wound Median |
|
79% |
57% |
$87 |
$7 |
|
$78 |
$0.7 |
-$4 |
0.8 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
|
74% |
153% |
$1,354 |
$173 |
|
$1,272 |
$3.0 |
-$46 |
3.2 |
|
3.7 |
|
|
| Grand Median |
|
76% |
106% |
$290 |
$72 |
|
$226 |
$1.8 |
-$27 |
2.0 |
|
1.1 |
|
|
originally published 04/14/2004 |